Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community

Journal of Hypertension

Volumn 27, Issue 6, 2009, Pages 1317-1324

  Joseph, Jacob ^a,b   Pencina, Michael J ^b   Wang, Thomas J ^c   Hayes, Laura ^b   Tofler, Geoffrey H ^d   Jacques, Paul ^e   Selhub, Jacob ^e   Levy, Daniel ^d   D'Agostino Sr , Ralph B ^d   Benjamin, Emelia J ^b,d   Vasan, Ramachandran S ^b,d  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d FRAMINGHAM HEART STUDY   (United States)

^e TUFTS UNIVERSITY   (United States)

Author keywords

Biomarkers; Cardiac remodeling; Collagen; Hyperhomocysteinemia; Matrix

Indexed keywords

ALDOSTERONE; AMINO TERMINAL PROATRIAL NATRIURETIC PEPTIDE; AMINO TERMINAL PROPEPTIDE OF TYPE 3 COLLAGEN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; GELATINASE B; HOMOCYSTEINE; NATRIURETIC FACTOR; PEPTIDE DERIVATIVE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; COLLAGEN METABOLISM; COMMUNITY SAMPLE; CONTROLLED STUDY; FEMALE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 67649655795     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328329fc20     Document Type: Article

References (34)

1. Orbe J, Fernandez L, Rodriguez JA, Rabago G, Belzunce M, Monasterio A, et al. Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis 2003; 170:269-276.
2. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and the renin-angiotensin-aldosterone system. Circulation 1991; 83:1849-1865.
3. Lopez B, Gonzalez A, Querejeta R, Diez J. The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. J Hypertens 2005; 23:1445-1451.
4. Laviades C, Mayor G, Diez J. Treatment with lisinopril normalizes serum concentrations of procollagen type III amino-terminal peptide in patients with essential hypertension. Am J Hypertens 1994; 7:52-58.
5. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coli Cardiol 1998; 32:368-372.
6. Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, et al. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur Heart J 2004; 25:1509-1516.
7. Maki T, Horio T, Yoshihara F, Suga S, Takeo S, Matsuo H, Kangawa K. Effect of neutral endopeptidase inhibitor on endogenous atrial natriuretic peptide as a paracrine factor in cultured cardiac fibroblasts. Br J Pharmacol 2004; 131:1204-1210.
8. Chuang-Tsai S, Sisson TH, Hattori N, Tsai CG, Subbotina NM, Hanson KE, Simon RH. Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1. Am J Pathol 2003; 163:445-452.
9. Nicoletti A, Michel JB. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res 1999; 41: 532-543.
10. Joseph J, Washington A, Joseph L, Koehler L, Fink LM, Hauer-Jensen M, Kennedy RH. Hyperhomocysteinemia leads to adverse cardiac remodeling and dysfunction in hypertensive rats. Am J Physiol 2002; 283:H2567- H2574.
11. Joseph J, Joseph L, Shekhawat N, Devi S, Wang J, Melchert RB, et al. Hyperhomocysteinemia leads to pathologic ventricular hypertrophy in normotensive rats. Am J Physiol Heart Circ Physiol 2003; 285:H679-H686.
12. Kannel WB, Feinleib M, McNmara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol 1979; 110:281-290.
13. Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004; 109:2850-2856.
14. Kathiresan S, Gona P, Larson MG, Vita JA, Mitchell GF, Tofler GH, et al. Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation 2006; 113:938-945.
15. Vasan RS, Evans JC, Benjamin EJ, Levy D, Larson MG, Sundstrom J, et al. Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertension 2004; 43:957-962.
16. Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF, et al. Plasma homocysteine and riskfor congestive heart failure in adults without prior myocardial infarction. JAMA 2003; 289:1251-1257.
17. Wang TJ, Larson MG, Benjamin EJ, Siwik DA, Safa R, Guo CY, et al. Clinical and echocardiographic correlates of plasma procollagen type III amino-terminal peptide levels in the community. Am Heart J 2007; 154:291-297.
18. Sundstrom J, Vasan RS. Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr Opin Lipidol 2006; 17:45-53.
19. Poulsen SH, Host NB, Jensen SE, Egstrup K. Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation 2000; 101:1527-1532.
20. Cui R, Moriyama Y, Koike KA, Date C, Kikuchi S, Tamakoshi A, Iso H. Serum total homocysteine concentrations and risk of mortality from stroke and coronary heart disease in Japanese: the JACC study. Atherosclerosis 2008; 198:412-418.
21. Miller A, Mujumdar V, Palmer L, Bower JD, Tyagi SC Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens 2002; 15 (2 Pt 1):157-1 63.
22. Walker E, Black J, Parris C, Bryda EC, Cansino S, Hunt L, et al. Effect of experimental hyperhomocysteinemia on cardiac structure and function in the rat. Ann Clin Lab Sci 2004; 34:175-1 80.
23. Sundstrom J, Sullivan L, Selhub J, Benjamin EJ, D'Agostino RB, Jacques PF, et al. Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study. Eur Heart J 2004; 25:523-530.
24. Cesari M, Zanchetta M, Burlina A, Pedon L, Maiolino G, Sticchi D, et al. Hyperhomocysteinemia is inversely associated with left ventricular ejection fraction and predicts cardiovascular mortality in high-risk coronary artery disease hypertensives. Arterioscl Thromb Vasc Biol 2005; 25:115-121.
25. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease: enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17:2074-2081.
26. Torres L, Garcia-Trevijano ER, Rodriguez JA, Carretero MV, Bustos M, Fernandez E, et al. Induction of TIMP-1 expression in rat hepatic stellate cells and hepatocytes: a new role for homocysteine in liverfibrosis. Biochim Biophys Acta 1999; 1455:12-22.
27. Doronzo G, Russo I, Mattiello L, Trovati M, Anfossi G. Homocysteine rapidly increases matrix metalloproteinase-2 expression and activity in cultured human vascular smooth muscle cells. Role of phosphatidyl inositol 3-kinase and mitogen activated protein kinase pathways. Thromb Haemost 2005; 94:1285-1293.
28. Moriwaki H, Stempien-Otera A, Kremen M, Cozen AE, Dichek DA. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type-1 causes cardiac fibrosis in mice. Circ Res 2004; 95:637-644.
29. lhara A, Kawamoto T, Matsumotot K, Kawamoto J, Katayama A, Yoshitatsu M, et al. Relationship between hemostatic markers and circulating biochemical markers of collagen metabolism in patients with aortic aneurysm. Pathophysiol Haemostat Thromb 2003; 33:221-224.
30. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339:321-328.
31. Franco V, Chen Y-F, Oparil S, Feng JA, Wang D, Hage F, Perry G. Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling. Hypertension 2004; 44:746-750.
32. Magga J, Puhakka M, Hietakorpi S, Punnonen K, Uusimaa P, Risteli J, et al. Atrial natriuretic peptide, B-type natriuretic peptide, and serum collagen markers after acute myocardial infarction. J Applied Physiol 2004; 96:1306-1311.
33. Montero I, Orbe J, Varo N, Beloqui O, Monreal Jl, Rodriguez JA, et al. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 2006; 47:1369-1378.
34. Newton-Cheh C, Guo C-Y, Gona P, Larson MG, Benjamin EJ, Wang TJ, et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007; 49:846-856.